Nastech Pharmaceutical Co has raised approximately $4.2 million in grossproceeds through a private sale of 860,000 newly-issued shares. The "select group of investors" that took part in the placement included SAFECO Growth Opportunities Fund and an asset management division of a "leading money center bank." Jesup & Lamont Securities Corporation acted as agent for Nastech.
Steven Quay, the firm's chief executive, said that with this financing, "Nastech has attracted an elite group of biomedical investors and secured additional resources to fund ongoing R&D and working capital."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze